Академический Документы
Профессиональный Документы
Культура Документы
harma's global heavyweights are boosting their presence in China in a large way as
they seek to fill a
growing need in areas such as oncology, arthritis and other diseases. And
surprisingly, much of the investment is going to R&D facilities.
which has four sites in China, representing its core pharmaceutical and diagnostics
businesses. Roche has two
sites in both Hong Kong and mainland China, employing about Roche opened its
Pharma Development Center in Shanghai last 1,400. October.
Yuan says the center employs about 100 staff members. Its focus is
developing compounds for oncology, autoimmune and metabolic
diseases, and anemia therapies for both China and global
development.
"This is the first time not only from Roche but also from the entire
pharma industry that all the components required to develop a product
from start to finish in the dinical development phase have been brought
to Asia Pacific, excluding Japan," Yuan says. "This includes fully
functioning development capacities which span from innovative early
exploratory dinical development strategies, to efficient late-stage clinical
development programs, to successful regulatory filings."
Yuan says that, currently, Chinese patients must wait four to five years for
medicines that were already approved in the U.S. or the European Union. The
center positions Roche to
Shanghai, "To minimize the lag time, the center aims to acquire local data and will
initiate and execute ciinical programs in collaboration with Roche's global
development organization, " Yuan says.
China's central and local governments are helping, she adds. "Roche has full
confidence that the Chinese government and authorities are committed to
appropriate IP protection to enable the further development of innovation-
based industry in China, " Yuan says. "Successfully capitalizing on innovation
requires protection of intellectual property by a patent law system that is in
line with international standards.
97
kelas berat global harma meningkatkan kehadiran mereka di Cina secara besar-
besaran ketika mereka berusaha mengisi
yang memiliki empat lokasi di China, yang mewakili bisnis inti farmasi dan
diagnostiknya. Roche memiliki dua
situs di Hong Kong dan daratan Cina, yang mempekerjakan Roche membuka Pusat
Pengembangan Farmasinya di 1.400 orang terakhir di Shanghai. Oktober.
"Ini adalah pertama kalinya tidak hanya dari Roche tetapi juga dari
seluruh industri farmasi bahwa semua komponen yang diperlukan untuk
mengembangkan produk dari awal hingga selesai dalam fase
pengembangan dinasional telah dibawa ke Asia Pasifik, tidak termasuk
Jepang," kata Yuan. "Ini termasuk kapasitas pengembangan yang
berfungsi penuh yang mencakup mulai dari strategi pengembangan
dinasional eksplorasi awal yang inovatif, hingga program
pengembangan klinis tahap akhir yang efisien, hingga pengajuan
peraturan yang berhasil."
Yuan mengatakan bahwa, saat ini, pasien Tiongkok harus menunggu empat
hingga lima tahun untuk obat-obatan yang sudah disetujui di AS atau Uni
Eropa. Posisi pusat Roche untuk
Roche Pharma mengurangi jeda waktu, yang sangat penting untuk terapi baru untuk penyakit seperti
kanker, yang memiliki Pusat Pengembangan menjadi lebih lazim di Cina.
Shanghai, "Untuk meminimalkan jeda waktu, pusat ini bertujuan untuk memperoleh
data lokal dan akan memulai dan melaksanakan program-program sipil bekerja sama
dengan organisasi pembangunan global Roche," kata Yuan.